In this study we evaluated the frequency of fusion between TMPRSS2 and ETS family members (ERG, ETV1, ETV4) in prostate cancers in patients from northern China in order to explore differences in fusion rates among regions in northern and southern China, other parts of Asia, Europe, and North America. We examined 100 prostate cancer patients, diagnosed by means of prostate biopsy; fluorescence in situ hybridization (FISH) was used to detect the expression of TMPRSS2, ERG, ETV1 and ETV4 in cancer tissue. Differences in gene fusion rates among different ethnics groups were also analyzed. Of the 100 prostate cancer patients, 55 (55%) had the fusion gene. Among the patients with the fusion gene, 46 (83.6%) patients had the TMPRSS2:ERG fusion product, 8 (14.8%) patients had TMPRSS2:ETV1 fusion, 1 (1.6%) patient had TMPRSS2:ETV4.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7314/apjcp.2012.13.10.4935 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression.
Mol Oncol
October 2024
UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut Pasteur de Lille, Univ. Lille, CNRS, Inserm, CHU Lille, France.
Prostate cancer, the most common malignancy in men, has a relatively favourable prognosis. However, when it spreads to the bone, the survival rate drops dramatically. The development of bone metastases leaves patients with aggressive prostate cancer, the leading cause of death in men.
View Article and Find Full Text PDFTMPRSS2::ETS translocation in nonprostatic malignancies: an unexpected finding in thymic carcinoma and pulmonary adenocarcinoma.
Virchows Arch
September 2024
Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary.
TMPRSS2::ETS fusions occur in about half of the prostate adenocarcinomas and are generally considered characteristic and even diagnostic of this tumour. Despite this fact, the frequency of this fusion is not well established in other tumour types. Incidental identification of a TMPRSS2::ETV1 fusion in a thymic squamous cell carcinoma prompted us to assess 1758 solid tumours by next-generation sequencing panel for TMPRSS2::ETS fusions, including 1690 non-prostatic malignancies.
View Article and Find Full Text PDFCytohistological findings and diagnostic challenges in rare pediatric pulmonary mesenchymal malignancies: A report of two cases.
Diagn Cytopathol
April 2024
Department of Pulmonary Medicine, AIIMS Bhopal, Bhopal, India.
Pulmonary mesenchymal tumors are uncommon neoplasms and the data available on their clinical, cytohistomorphological, immunohistochemical, and molecular findings are limited, leading to difficulty in timely diagnosis and management. Case 1: A 12-year-old boy presented with a right endobronchial mass. Imprint smears from endobronchial biopsy revealed moderately pleomorphic spindle cell tumor arranged in fascicles and perivascular pattern with attached myxoid material showing occasional mitotic activity suggesting a cytological diagnosis of sarcoma.
View Article and Find Full Text PDFImmunohistochemical markers as predictors of prognosis in multifocal prostate cancer.
Virchows Arch
August 2024
Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
The impact of tumor focality on prostate cancer (PCa) prognosis has been addressed in several studies with conflicting results. Tumor foci from multifocal (MF) PCa can show highly heterogeneous molecular features. Our aim was to analyze the protein expression of PTEN, SPOP, SLC45A3, ETV1, ERG and the "triple hit" (ERG overexpression, PTEN plus SLC45A3 loss) in unifocal (UF) and MF PCa, to evaluate their value as prognostic markers according to focality, and the role of tumor heterogeneity in MF disease.
View Article and Find Full Text PDFCleavage and Polyadenylation-Specific Factor 4 (CPSF4) Expression Is Associated with Enhanced Prostate Cancer Cell Migration and Cell Cycle Dysregulation, In Vitro.
Int J Mol Sci
August 2023
Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
Potential oncogene cleavage and polyadenylation specific factor 4 (CPSF4) has been linked to several cancer types. However, little research has been conducted on its function in prostate cancer (PCa). In benign, incidental, advanced, and castrate resistant PCa (CRPCa) patient samples, protein expression of CPSF4 was examined on tissue microarray (TMAs) of 353 PCa patients using immunohistochemistry.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!